The Jenner Institute

The Jenner Institute
Name	The Jenner Institute
Established	1996
Type	Research institute
Location	Oxford, England
Parent	University of Oxford
Focus	Vaccine research, immunology, infectious diseases

The Jenner Institute

The Jenner Institute is a biomedical research institute based in Oxford focused on vaccine research and immunology, named after Edward Jenner and associated with the University of Oxford and the UK Research and Innovation landscape. It conducts translational research addressing infectious diseases such as malaria, tuberculosis, and COVID-19, and collaborates with international organizations, pharmaceutical companies, and academic partners to advance vaccine candidates from preclinical studies to clinical trials.

History

The Institute was founded through partnerships linking the University of Oxford with the Medical Research Council and the Wellcome Trust during a period of expansion in translational research linked to institutions such as the Nuffield Department of Medicine, the Sir William Dunn School of Pathology, and the Institute of Molecular Medicine. Early activities involved investigators with prior affiliations to the Rockefeller University, Imperial College London, and the London School of Hygiene & Tropical Medicine, and built upon historical legacies from figures like Edward Jenner and contemporaries in vaccine science who interacted with institutions such as the Royal Society and the Wellcome Collection. Over time the Institute integrated expertise from groups related to the Department of Zoology, University of Oxford, the Centre for Tropical Medicine and Global Health, and clinical research units linked to the NHS and the Oxford University Hospitals NHS Foundation Trust.

Research and Vaccine Development

The Institute’s research spans antigen discovery, vector platforms, and human challenge studies, with programs addressing pathogens including Plasmodium falciparum, Mycobacterium tuberculosis, SARS-CoV-2, Ebola virus, Lassa virus, and Zika virus. Platform technologies include viral vectors related to adenovirus systems and recombinant proteins informed by work in laboratories such as the Scripps Research Institute and the National Institutes of Health. Clinical development pathways have engaged regulatory authorities like the Medicines and Healthcare products Regulatory Agency and trial networks including the Oxford Vaccine Group and the European Vaccine Initiative. Translational science at the Institute draws on comparative work with vaccine efforts at the Centers for Disease Control and Prevention, Institut Pasteur, Karolinska Institutet, Johns Hopkins University, and the Bill & Melinda Gates Foundation-supported consortia.

Facilities and Affiliated Institutions

Facilities supporting the Institute include laboratories within the Jenner Institute building complex on the University of Oxford campus, containment suites aligned to standards from the World Health Organization, and biomanufacturing capacity linked to academic spin-outs and contract manufacturers that have worked with companies such as AstraZeneca, Pfizer, and GlaxoSmithKline. Affiliated units include the Nuffield Department of Medicine, the Department of Paediatrics, University of Oxford, the Radcliffe Department of Medicine, and hospital partners including John Radcliffe Hospital and clinics involved in phase I–III trials. Collaborative clinical research sites extend to partner institutions in Kenya, Thailand, South Africa, and Brazil, working with organizations such as the Kenya Medical Research Institute, the Thai Ministry of Public Health, the South African Medical Research Council, and the Fiocruz network.

Collaborations and Partnerships

The Institute has established partnerships with global health funders and industry players including the Wellcome Trust, the Bill & Melinda Gates Foundation, GlaxoSmithKline, AstraZeneca, and Oxford University Innovation spin-outs. Academic collaborations include joint projects with Imperial College London, Cambridge University, Harvard Medical School, Yale School of Medicine, Karolinska Institutet, and the European Commission research programs. International public-health collaborations link to agencies such as the World Health Organization, the Coalition for Epidemic Preparedness Innovations, and regional bodies like the African Union. Clinical trial consortia have coordinated with the National Institute for Health and Care Research, the European Medicines Agency, and networks including ISARIC.

Funding and Governance

Funding streams combine charitable awards from the Wellcome Trust and philanthropic support from donors such as the Bill & Melinda Gates Foundation and institutional grants from the Medical Research Council and the National Institute for Health Research. Industry-sponsored projects have involved collaborations with multinational corporations including AstraZeneca, Pfizer, and GlaxoSmithKline. Governance structures align with the University of Oxford’s research governance, oversight by boards with membership drawn from institutions like the Nuffield College, the Oxford Martin School, and advisory input from stakeholders including the UK Department of Health and Social Care and international partners such as the Gavi, the Vaccine Alliance.

Notable Achievements and Impact

Notable outputs include progression of vaccine candidates into human trials, contributions to the rapid development of SARS-CoV-2 vaccine programs in partnership with AstraZeneca and trial networks including the Oxford Vaccine Group, and advances in malaria vaccine candidates that have informed policy discussions at the World Health Organization. The Institute’s work has intersected with public-health responses coordinated by the National Health Service, informed guidelines from the European Centre for Disease Prevention and Control, and influenced global vaccine-access initiatives convened by entities such as Gavi, the Vaccine Alliance and the Global Fund. Its translational approach has spawned collaborations with spin-outs and biotech companies, academic awards, and participation in international consortia addressing emerging pathogens including Ebola, Lassa fever, and Zika virus.

Category:Research institutes in the United Kingdom Category:University of Oxford